Window watching

Reading the tea leaves in the biotech IPO market

The valuations and prices of January’s trio of biotech IPOs on NASDAQ appear encouraging. But with the stocks’ aftermarket performances falling short of expectations and one deal fizzling, investors are likely to remain picky about new paper for now.

Read the full 393 word article

User Sign In